SEC Tracker
Get the app

Iridex IRIX

Iridex Q3 FY25: revenue $12.5M, up 8%; diluted EPS −$0.09

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Iridex reported for Q3 FY25, the quarter ended Sep 27, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$12.5M+8% from $11.6M in Q3 FY2410-Q income statement, on EDGAR
  2. Net income−$1.6MAgainst −$1.9M in Q3 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$0.09Against −$0.12 in Q3 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$5.6M+44% from $3.9M in Q3 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations−$1.2MAgainst −$3.1M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Iridex files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.

  1. Nexalin Technology NXL public float $15M, Jun 30, 2025
  2. Biotricity BTCY public float $13M, Sep 30, 2025
  3. Beyond Air XAIR public float $16M, Sep 30, 2025
  4. RetinalGenix Technologies RTGN public float $16M, Jun 30, 2025
  5. Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.